Lysoway Therapeutics published preclinical data on LW-1017, a brain-penetrant small-molecule agonist of the lysosomal calcium channel TRPML1 that activates the TFEB-driven CLEAR gene network governing autophagy and lysosomal function. In aged animal models, oral dosing lowered pathological alpha-synuclein, amyloid and tau, preserved dopaminergic neurons, reduced neuroinflammation and improved motor and cognitive performance. The compound is now in a Phase I single and multiple ascending dose study in healthy volunteers.
Key Points
- TRPML1 agonist activates TFEB and lysosomal CLEAR gene network
- Reduced alpha-synuclein, amyloid and tau in aged models
- Phase I ascending dose trial underway in healthy volunteers
Longevity Analysis
Declining autophagy-lysosomal capacity is one of the more consistent features of brain aging, and protein aggregates accumulate in part because intracellular clearance machinery loses throughput rather than because production suddenly accelerates. Targeting the lysosome as the disposal hub, instead of any single misfolded protein, shifts the emphasis toward restoring the cell's own waste-handling and repair capacity — the same capacity supported by fasting intervals, sleep quality, exercise, and reduced toxic load. The parallel reduction in neuroinflammation suggests improved clearance and calmer immune signaling in brain tissue move together, and a pharmacological lever of this kind would complement, not replace, the daily practices that keep that machinery working.
Original published by LT Wire.